HAART for children with treatment failure
HAART for children with treatment failure
复制标题
DOI：
10.2217/hiv.09.28
复制
发表时间：
2009-09-01
期刊：
影响因子：
--
通讯作者：
Ananworanich, Jintanat
中科院分区：
文献类型：
--
作者：
Sohn, Annette H.;Ananworanich, Jintanat
尽管儿科推广计划正在努力满足全球需求，但在低收入和中等收入国家，越来越多的儿童无法接受一线抗逆转录病毒治疗。如果不能更好地进行病毒载量监测、二线抗逆转录病毒药物和指导最佳治疗方案选择的研究，就难以确保感染艾滋病毒的儿童能够活到成年。关于儿科耐药性的现有数据表明，失败发生在儿童早期。挽救药物选择的研究一直很有希望，但主要是在成人中进行的。现在需要对方案选择、儿科抗逆转录病毒制剂和扩大获得新药的机会采取循证办法，以便为未来做好准备。
Even as pediatric rollout programs are struggling to meet global need, increasing numbers of children are failing first-line antiretroviral therapy in low- and middle-income countries. Without better access to viral load monitoring, second-line antiretrovirals and research to guide optimal regimen selection, it will be difficult to ensure that HIV-infected children will survive into adulthood. Data available on pediatric drug resistance demonstrate that failure occurs early in childhood. Studies of salvage drug options have been promising, but are primarily conducted in adults. Evidence-based approaches to regimen selection, pediatric antiretroviral formulations and expanded access to novel drugs are now required to prepare for the future.